Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed CD20-positive diffuse large B-cell non-Hodgkin lymphoma (DLBCL) according to the current WHO classification, including all morphological variants~  * Newly diagnosed disease~ * Bulky stage IA-IV disease~    * No non-bulky stage IA disease~* Measurable disease~* Not eligible for CHOP chemotherapy due to impaired cardiac function~  * Cardiac status that does not allow the administration of 8 courses of R-CHOP chemotherapy, as defined by 1 of the following criteria:~    * Ejection fraction less than 50% as assessed by either ECHO or MUGA scan~   * NYHA class III-IV~* No high-grade transformation of low-grade lymphoma~* No symptomatic central nervous system or meningeal involvement by the lymphoma~* No AIDS-related lymphoma~PATIENT CHARACTERISTICS:~* ECOG performance status 0-3~* Life expectancy \> 3 months~* Platelet count \> 100 x 10\^9/L~* WBC \> 3 x 10\^9/L~* Neutrophils \> 1.5 x 10\^9/L (unless elevated level attributed to bone marrow infiltration by lymphoma)~* Serum bilirubin \< 50 μmol/L~* Transaminases \< 2.5 times upper limit of normal (unless elevated level attributed to lymphoma)~* Glomerular filtration rate \> 30 mL/min~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No other concurrent uncontrolled medical condition~* No active malignant disease, other than non-melanotic skin cancer or carcinoma in situ of the uterine cervix, within the past 10 years~* No positive serology for HIV~* No medical or psychiatric conditions that compromise the patient's ability to give informed consent~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy, radiotherapy, or other investigational drug for this indication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- R-GCVP (Type: EXPERIMENTAL): Up to 6 x 21 day cycles of R-GCVP:~* Gemcitabine 750mg/m\^2 days 1 \& 8 (increasing to 875mg/m\^2 for cycle 2 \& 1g/m\^2 for subsequent cycles if tolerated satisfactorily)~* Cyclophosphamide 750mg/m\^2 day 1~* Vincristine 1.4mg/m\^2 day 1 (capped at 2mg)~* Prednisolone 100mg/day days 1-5~* Rituximab 375mg/m\^2 day 1~* Neulasta 6mg day 9

Based on this trial design, predict the completion outcome and termination type (if applicable).